Fate Therapeutics Inc’s recently made public that its insider Bressi Jerome Charles unloaded Company’s shares for reported $9269.0 on Jan 10 ’25. In the deal valued at $1.55 per share,5,980 shares were sold. As a result of this transaction, Bressi Jerome Charles now holds 270,203 shares worth roughly $0.35 million.
Then, TAHL CINDY sold 5,654 shares, generating $8,764 in total proceeds. Upon selling the shares at $1.55, the insider now owns 336,707 shares.
Before that, Valamehr Bahram sold 8,705 shares. Fate Therapeutics Inc shares valued at $13,406 were divested by the President and CEO at a price of $1.54 per share. As a result of the transaction, Valamehr Bahram now holds 349,364 shares, worth roughly $0.45 million.
BofA Securities upgraded its Fate Therapeutics Inc [FATE] rating to a Neutral from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who increased its forecast for the stock in mid June from “a Neutral” to “an Overweight”. H.C. Wainwright revised its rating on January 24, 2023. It rated FATE as “a Neutral” which previously was an “a Buy”.
Price Performance Review of FATE
On Monday, Fate Therapeutics Inc [NASDAQ:FATE] saw its stock fall -11.95% to $1.29. Over the last five days, the stock has lost -28.33%. Fate Therapeutics Inc shares have fallen nearly -21.82% since the year began. Nevertheless, the stocks have fallen -71.77% over the past one year. While a 52-week high of $8.83 was reached on 01/06/25, a 52-week low of $1.45 was recorded on 01/13/25. SMA at 50 days reached $2.1728, while 200 days put it at $3.5619.
Levels Of Support And Resistance For FATE Stock
The 24-hour chart illustrates a support level at 1.2300, which if violated will result in even more drops to 1.1700. On the upside, there is a resistance level at 1.4000. A further resistance level may holdings at 1.5100. The Relative Strength Index (RSI) on the 14-day chart is 29.91, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1775, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.59%. Stochastics %K at 10.29% indicates the stock is a buying.
How much short interest is there in Fate Therapeutics Inc?
A steep rise in short interest was recorded in Fate Therapeutics Inc stocks on 2024-12-13, growing by 1.8 million shares to a total of 12.19 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 10.39 million shares. There was a rise of 14.75%, which implies that there is a positive sentiment for the stock.
